Percutaneous cryoablation for the treatment of medically inoperable Stage I non-small cell lung cancer

Yoshikane Yamauchi, Yotaro Izumi, Kohei Hashimoto, Hideki Yashiro, Masanori Inoue, Seishi Nakatsuka, Taichiro Goto, Masaki Anraku, Takashi Ohtsuka, Mitsutomo Kohno, Masafumi Kawamura, Hiroaki Nomori

研究成果: Article

45 引用 (Scopus)

抄録

Background: To evaluate the midterm results of percutaneous cryoablation for medically inoperable stage I non-small cell lung cancer. Methodology/Principal Findings: Between January 2004 and June 2010, 160 patients underwent computer tomography guided percutaneous cryoablation for lung tumors at our institution. Of these patients, histologically proven stage I lung cancer patients with more than one year of follow-up, were retrospectively reviewed. All of these patients were considered to be medically inoperable with Charlson comorbidity index of 3 or greater. Follow-up was based primarily on computed tomography. There were 22 patients with 34 tumors who underwent 25 sessions of cryoablation treatment. Complications were pneumothoraces in 7 treatments (28%, chest tube required in one treatment), and pleural effusions in 8 treatments (31%). The observation period ranged from 12-68 months, average 29±19 months, median 23 months. Local tumor progression was observed in one tumor (3%). Mean local tumor progression-free interval was 69±2 months. One patient died of lung cancer progression at 68 months. Two patients died of acute exacerbations of idiopathic pulmonary fibrosis which were not considered to be directly associated with cryoablation, at 12 and 18 months, respectively. The overall 2- and 3-year survivals were 88% and 88%, respectively. Mean overall survival was 62±4 months. Median overall survival was 68 months. The disease-free 2- and 3-year survivals were 78% and 67%, respectively. Mean disease-free survival was 46±6 months. Pulmonary function tests were done in 16 patients (18 treatments) before and after cryoablation. Percentage of predicted vital capacity, and percentage of predicted forced expiratory volume in 1 second, did not differ significantly before and after cryoablation (93±23 versus 90±21, and 70±11 versus 70±12, respectively). Conclusions/Significance: Although further accumulation of data is necessary regarding efficacy, cryoablation may be a feasible option in medically inoperable stage I lung cancer patients.

元の言語English
記事番号e33223
ジャーナルPLoS One
7
発行部数3
DOI
出版物ステータスPublished - 2012 3 8

Fingerprint

Cryosurgery
lung neoplasms
Non-Small Cell Lung Carcinoma
Tumors
Cells
Tomography
cells
Patient treatment
Lung Neoplasms
neoplasms
Therapeutics
Survival
Neoplasms
pneumothorax
Chest Tubes
Idiopathic Pulmonary Fibrosis
lung function
Respiratory Function Tests
tomography
Vital Capacity

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

これを引用

Percutaneous cryoablation for the treatment of medically inoperable Stage I non-small cell lung cancer. / Yamauchi, Yoshikane; Izumi, Yotaro; Hashimoto, Kohei; Yashiro, Hideki; Inoue, Masanori; Nakatsuka, Seishi; Goto, Taichiro; Anraku, Masaki; Ohtsuka, Takashi; Kohno, Mitsutomo; Kawamura, Masafumi; Nomori, Hiroaki.

:: PLoS One, 巻 7, 番号 3, e33223, 08.03.2012.

研究成果: Article

Yamauchi, Y, Izumi, Y, Hashimoto, K, Yashiro, H, Inoue, M, Nakatsuka, S, Goto, T, Anraku, M, Ohtsuka, T, Kohno, M, Kawamura, M & Nomori, H 2012, 'Percutaneous cryoablation for the treatment of medically inoperable Stage I non-small cell lung cancer', PLoS One, 巻. 7, 番号 3, e33223. https://doi.org/10.1371/journal.pone.0033223
Yamauchi, Yoshikane ; Izumi, Yotaro ; Hashimoto, Kohei ; Yashiro, Hideki ; Inoue, Masanori ; Nakatsuka, Seishi ; Goto, Taichiro ; Anraku, Masaki ; Ohtsuka, Takashi ; Kohno, Mitsutomo ; Kawamura, Masafumi ; Nomori, Hiroaki. / Percutaneous cryoablation for the treatment of medically inoperable Stage I non-small cell lung cancer. :: PLoS One. 2012 ; 巻 7, 番号 3.
@article{3ce369dee34e431a84e07e5201768186,
title = "Percutaneous cryoablation for the treatment of medically inoperable Stage I non-small cell lung cancer",
abstract = "Background: To evaluate the midterm results of percutaneous cryoablation for medically inoperable stage I non-small cell lung cancer. Methodology/Principal Findings: Between January 2004 and June 2010, 160 patients underwent computer tomography guided percutaneous cryoablation for lung tumors at our institution. Of these patients, histologically proven stage I lung cancer patients with more than one year of follow-up, were retrospectively reviewed. All of these patients were considered to be medically inoperable with Charlson comorbidity index of 3 or greater. Follow-up was based primarily on computed tomography. There were 22 patients with 34 tumors who underwent 25 sessions of cryoablation treatment. Complications were pneumothoraces in 7 treatments (28{\%}, chest tube required in one treatment), and pleural effusions in 8 treatments (31{\%}). The observation period ranged from 12-68 months, average 29±19 months, median 23 months. Local tumor progression was observed in one tumor (3{\%}). Mean local tumor progression-free interval was 69±2 months. One patient died of lung cancer progression at 68 months. Two patients died of acute exacerbations of idiopathic pulmonary fibrosis which were not considered to be directly associated with cryoablation, at 12 and 18 months, respectively. The overall 2- and 3-year survivals were 88{\%} and 88{\%}, respectively. Mean overall survival was 62±4 months. Median overall survival was 68 months. The disease-free 2- and 3-year survivals were 78{\%} and 67{\%}, respectively. Mean disease-free survival was 46±6 months. Pulmonary function tests were done in 16 patients (18 treatments) before and after cryoablation. Percentage of predicted vital capacity, and percentage of predicted forced expiratory volume in 1 second, did not differ significantly before and after cryoablation (93±23 versus 90±21, and 70±11 versus 70±12, respectively). Conclusions/Significance: Although further accumulation of data is necessary regarding efficacy, cryoablation may be a feasible option in medically inoperable stage I lung cancer patients.",
author = "Yoshikane Yamauchi and Yotaro Izumi and Kohei Hashimoto and Hideki Yashiro and Masanori Inoue and Seishi Nakatsuka and Taichiro Goto and Masaki Anraku and Takashi Ohtsuka and Mitsutomo Kohno and Masafumi Kawamura and Hiroaki Nomori",
year = "2012",
month = "3",
day = "8",
doi = "10.1371/journal.pone.0033223",
language = "English",
volume = "7",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "3",

}

TY - JOUR

T1 - Percutaneous cryoablation for the treatment of medically inoperable Stage I non-small cell lung cancer

AU - Yamauchi, Yoshikane

AU - Izumi, Yotaro

AU - Hashimoto, Kohei

AU - Yashiro, Hideki

AU - Inoue, Masanori

AU - Nakatsuka, Seishi

AU - Goto, Taichiro

AU - Anraku, Masaki

AU - Ohtsuka, Takashi

AU - Kohno, Mitsutomo

AU - Kawamura, Masafumi

AU - Nomori, Hiroaki

PY - 2012/3/8

Y1 - 2012/3/8

N2 - Background: To evaluate the midterm results of percutaneous cryoablation for medically inoperable stage I non-small cell lung cancer. Methodology/Principal Findings: Between January 2004 and June 2010, 160 patients underwent computer tomography guided percutaneous cryoablation for lung tumors at our institution. Of these patients, histologically proven stage I lung cancer patients with more than one year of follow-up, were retrospectively reviewed. All of these patients were considered to be medically inoperable with Charlson comorbidity index of 3 or greater. Follow-up was based primarily on computed tomography. There were 22 patients with 34 tumors who underwent 25 sessions of cryoablation treatment. Complications were pneumothoraces in 7 treatments (28%, chest tube required in one treatment), and pleural effusions in 8 treatments (31%). The observation period ranged from 12-68 months, average 29±19 months, median 23 months. Local tumor progression was observed in one tumor (3%). Mean local tumor progression-free interval was 69±2 months. One patient died of lung cancer progression at 68 months. Two patients died of acute exacerbations of idiopathic pulmonary fibrosis which were not considered to be directly associated with cryoablation, at 12 and 18 months, respectively. The overall 2- and 3-year survivals were 88% and 88%, respectively. Mean overall survival was 62±4 months. Median overall survival was 68 months. The disease-free 2- and 3-year survivals were 78% and 67%, respectively. Mean disease-free survival was 46±6 months. Pulmonary function tests were done in 16 patients (18 treatments) before and after cryoablation. Percentage of predicted vital capacity, and percentage of predicted forced expiratory volume in 1 second, did not differ significantly before and after cryoablation (93±23 versus 90±21, and 70±11 versus 70±12, respectively). Conclusions/Significance: Although further accumulation of data is necessary regarding efficacy, cryoablation may be a feasible option in medically inoperable stage I lung cancer patients.

AB - Background: To evaluate the midterm results of percutaneous cryoablation for medically inoperable stage I non-small cell lung cancer. Methodology/Principal Findings: Between January 2004 and June 2010, 160 patients underwent computer tomography guided percutaneous cryoablation for lung tumors at our institution. Of these patients, histologically proven stage I lung cancer patients with more than one year of follow-up, were retrospectively reviewed. All of these patients were considered to be medically inoperable with Charlson comorbidity index of 3 or greater. Follow-up was based primarily on computed tomography. There were 22 patients with 34 tumors who underwent 25 sessions of cryoablation treatment. Complications were pneumothoraces in 7 treatments (28%, chest tube required in one treatment), and pleural effusions in 8 treatments (31%). The observation period ranged from 12-68 months, average 29±19 months, median 23 months. Local tumor progression was observed in one tumor (3%). Mean local tumor progression-free interval was 69±2 months. One patient died of lung cancer progression at 68 months. Two patients died of acute exacerbations of idiopathic pulmonary fibrosis which were not considered to be directly associated with cryoablation, at 12 and 18 months, respectively. The overall 2- and 3-year survivals were 88% and 88%, respectively. Mean overall survival was 62±4 months. Median overall survival was 68 months. The disease-free 2- and 3-year survivals were 78% and 67%, respectively. Mean disease-free survival was 46±6 months. Pulmonary function tests were done in 16 patients (18 treatments) before and after cryoablation. Percentage of predicted vital capacity, and percentage of predicted forced expiratory volume in 1 second, did not differ significantly before and after cryoablation (93±23 versus 90±21, and 70±11 versus 70±12, respectively). Conclusions/Significance: Although further accumulation of data is necessary regarding efficacy, cryoablation may be a feasible option in medically inoperable stage I lung cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=84857855632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857855632&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0033223

DO - 10.1371/journal.pone.0033223

M3 - Article

C2 - 22413004

AN - SCOPUS:84857855632

VL - 7

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 3

M1 - e33223

ER -